There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Vaxcyte Inc. (PCVX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $53.10. The Vaxcyte Inc. has recorded 14,239 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update.
As a NASDAQ listed company, PCVX falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $53.10 and fluctuated between $53.48 as its day high and $52.10 as its day low. The current market capitalization of Vaxcyte Inc. is $4.87B. A total of 0.41 million shares were traded on the day, compared to an average of 543.81K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, PCVX has seen 7 BUY and 1 SELL insider trades, representing the acquisition of 17,500 and the disposition of 645 shares. Over the last 12 months, there were 24 BUYs and 27 SELLs from insiders. Insiders purchased 306,285 shares during that period but sold 68,360.
In the most recent transaction, Lukatch Heath sold 315 shares of PCVX for 46.12 per share on Jan 10. After the transaction, the Director now owns 3,125 company shares. In a previous transaction on Dec 12, Lukatch Heath sold 335 shares at 43.93 per share. PCVX shares that Director owns now total 3,125.
Among the insiders who sold shares, Lukatch Heath disposed of 4,335 shares on Nov 10 at a per-share price of $46.13. This resulted in the Director holding 3,125 shares of PCVX after the transaction. In another insider transaction, Fairman Jeff sold 10,000 shares at $40.00 per share on Oct 26. Company shares held by the VP, Research now total 286,227.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for PCVX in the last 3 months, the mean price target is $66.14 with high estimates of $72.00 and low estimates of $58.00. In terms of 52-week highs and lows, PCVX has a high of $54.97 and a low of $20.49.
As of this writing, PCVX has an earnings estimate of -$0.84 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.73 per share and a lower estimate of -$0.96. The company reported an EPS of -$0.7 in the last quarter, which was 15.70% higher than expectations of -$0.83.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. PCVX’s latest balance sheet shows that the firm has $245.97M in Cash & Short Term Investments as of fiscal 2021. There were $16.78M in debt and $28.72M in liabilities at the time. Its Book Value Per Share was $14.62, while its Total Shareholder’s Equity was $284.02M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PCVX is Buy with a score of 4.88.